<DOC>
	<DOCNO>NCT01239485</DOCNO>
	<brief_summary>The purpose study determine maximum tolerable dose irinotecan combination etoposide , cytarabine refractory relapse acute leukemia pediatric patient .</brief_summary>
	<brief_title>Study IRNEA ( Irinotecan , Etoposide , Cytarabine ) Refractory Relapsed Acute Leukemia Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Diagnosis ALL AML . Prior therapy Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . ALL patient must two prior therapeutic attempt define Persistent ( BM blast &gt; 5 % ) initial disease two induction attempt , Persistent ( BM blast &gt; 5 % ) reinduction attempt first relapse Relapse one reinduction attempt ( 2nd relapse ) AML patient must one prior therapeutic attempt define Refractory ( BM blast &gt; 20 % ) initial disease one induction attempt , Persistent ( BM blast &gt; 5 % ) initial disease two induction attempt , Relapse one induction attempt ( 1st relapse ) Relapse stem cell transplant : Patients eligible 12 week allogeneic stem cell transplant long patient actively treat GvHD recover transplantrelated toxicity . Patients eligible 8 week day stem cell infusion myeloablative autologous stem cell transplant , hematological eligibility criterion meet . Age : ≤ 21 year . Performance status : ECOG 02 . Patients must free significant functional deficit major organ , follow eligibility criterion may modify individual case . 1 . Heart : shortening fraction ≥ 28 % 2 . Liver : total bilirubin &lt; 2 × upper limit normal ; ALT &lt; 3 × upper limit normal . 3 . Kidney : creatinine &lt; 2 × normal creatinine clearance ( GFR ) &gt; 60 ml/min/1.73m2 . Patients must lack active viral infection active fungal infection . Patients ( one parent patient age &lt; 19 ) sign inform 1 . Pregnant nursing woman . 2 . Malignant ( except acute leukemia ) nonmalignant illness uncontrolled whose control may jeopardize complication study therapy . 3 . Psychiatric disorder would preclude compliance . 4 . Patients , opinion investigator , may able comply safety monitoring requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Pediatric refractory relapse acute leukemia</keyword>
</DOC>